n.a. (CADX)

0.00
NASDAQ
Prev Close 0.00
Day Low/High 0.00 / 0.00
52 Wk Low/High 0.00 / 0.00
Exchange NASDAQ
Market Cap 1.25B
Div & Yield N.A. (N.A)

Latest News

SHAREHOLDER DEADLINE: Law Office Of Brodsky & Smith, LLC Announces Investigation Of Cadence Pharmaceuticals, Inc.

SHAREHOLDER DEADLINE: Law Office Of Brodsky & Smith, LLC Announces Investigation Of Cadence Pharmaceuticals, Inc.

Law office of Brodsky & Smith, LLC announces that it is investigating potential claims against the Board of Directors of Cadence Pharmaceuticals, Inc.

CADENCE INVESTOR ALERT: Faruqi & Faruqi, LLP Is Investigating Cadence Pharmaceuticals, Inc. (CADX) In Relation To The Proposed Sale Of The Company To Mallinckrodt Plc

CADENCE INVESTOR ALERT: Faruqi & Faruqi, LLP Is Investigating Cadence Pharmaceuticals, Inc. (CADX) In Relation To The Proposed Sale Of The Company To Mallinckrodt Plc

Juan E. Monteverde, a partner at Faruqi & Faruqi, LLP, a leading national securities firm headquartered in New York City, is investigating the Board of Directors of Cadence Pharmaceuticals, Inc.

Cadence Pharmaceuticals Shareholder Alert: Former SEC Attorney Willie Briscoe And Powers Taylor LLP Investigate Sale To Mallinckrodt Plc

Cadence Pharmaceuticals Shareholder Alert: Former SEC Attorney Willie Briscoe And Powers Taylor LLP Investigate Sale To Mallinckrodt Plc

Former United States Securities and Exchange Commission attorney Willie Briscoe and the securities litigation firm of Powers Taylor LLP are investigating potential claims against the Board of Directors of Cadence...

Mallinckrodt Is Just One Of Dennis Kozlowski's Billion Dollar Babies

Mallinckrodt Is Just One Of Dennis Kozlowski's Billion Dollar Babies

Had you stuck with his stock after Kozlowski was charged in 2002 you might now be richly rewarded.

Law Firm Kirby McInerney LLP Investigating Potential Claims On Behalf Of Cadence Pharmaceuticals, Inc. Stockholders

Law Firm Kirby McInerney LLP Investigating Potential Claims On Behalf Of Cadence Pharmaceuticals, Inc. Stockholders

Kirby McInerney LLP is investigating potential claims against the Board of Directors of Cadence Pharmaceuticals, Inc.

Mallinckrodt Inks $1.3B Deal for Cadence

Mallinckrodt Inks $1.3B Deal for Cadence

Irish buyer offers a 26% premium to secure Cadence's Ofirmev injectable pain killer, which recently won approval in Canada.

Mallinckrodt Buys Cadence Pharma for $1.3 Billion

Mallinckrodt Buys Cadence Pharma for $1.3 Billion

Cadence sells an intravenous form of the painkiller acetaminophen used in hospitals.

Mallinckrodt Plc To Acquire Cadence Pharmaceuticals, Inc. For $14.00 Per Share, In Cash

Mallinckrodt Plc To Acquire Cadence Pharmaceuticals, Inc. For $14.00 Per Share, In Cash

Mallinckrodt plc (NYSE: MNK), a leading global specialty pharmaceuticals company, and Cadence Pharmaceuticals, Inc.

Interesting CADX Put And Call Options For August 2014

Interesting CADX Put And Call Options For August 2014

Investors in Cadence Pharmaceuticals Inc saw new options become available this week, for the August 2014 expiration. One of the key data points that goes into the price an option buyer is willing to pay, is the time value, so with 229 days until expiration the newly available contracts represent a possible opportunity for sellers of puts or calls to achieve a higher premium than would be available for the contracts with a closer expiration.

Biotech Stocks Partying Like It's 1999

Biotech Stocks Partying Like It's 1999

After a weak October, biotech stocks have rebounded in a big way in November. The sector is on pace for an history year of absolute and relative performance.

Interesting CADX Put And Call Options For January 2014

Interesting CADX Put And Call Options For January 2014

Investors in Cadence Pharmaceuticals Inc saw new options become available this week, for the January 2014 expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the CADX options chain for the new January 2014 contracts and identified one put and one call contract of particular interest.

Commit To Buy Cadence Pharmaceuticals At $5, Earn 16.3% Annualized

Commit To Buy Cadence Pharmaceuticals At $5, Earn 16.3% Annualized

Investors considering a purchase of Cadence Pharmaceuticals Inc shares, but tentative about paying the going market price of $6.21/share, might benefit from considering selling puts among the alternative strategies at their disposal. One interesting put contract in particular, is the February 2014 put at the $5 strike, which has a bid at the time of this writing of 35 cents.

Oversold Conditions For Cadence Pharmaceuticals (CADX)

Oversold Conditions For Cadence Pharmaceuticals (CADX)

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100.

Cadence Pharmaceuticals Stock Sees Short Interest Decline 25%

Cadence Pharmaceuticals Stock Sees Short Interest Decline 25%

The most recent short interest data has been released by the NASDAQ for the 08/15/2013 settlement date, which shows a 781,695 share decrease in total short interest for Cadence Pharmaceuticals Inc , to 2,361,133, a decrease of 24.87% since 07/31/2013. Total short interest is just one way to look at short data; another metric that we here at Dividend Channel find particularly useful is the "days to cover" metric because it considers both the total shares short and the average daily volume of shares traded.

CADX Makes Notable Cross Below Critical Moving Average

CADX Makes Notable Cross Below Critical Moving Average

In trading on Wednesday, shares of Cadence Pharmaceuticals Inc crossed below their 200 day moving average of $5.77, changing hands as low as $5.71 per share. Cadence Pharmaceuticals Inc shares are currently trading down about 4.2% on the day.

Short Interest In Cadence Pharmaceuticals Falls 10.2%

Short Interest In Cadence Pharmaceuticals Falls 10.2%

The most recent short interest data has been released by the NASDAQ for the 07/31/2013 settlement date, which shows a 356,691 share decrease in total short interest for Cadence Pharmaceuticals Inc , to 3,142,828, a decrease of 10.19% since 07/15/2013. Total short interest is just one way to look at short data; another metric that we here at Dividend Channel find particularly useful is the "days to cover" metric because it considers both the total shares short and the average daily volume of shares traded.

Cadence Pharmaceuticals Becomes Oversold (CADX)

Cadence Pharmaceuticals Becomes Oversold (CADX)

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100.

8 Stocks Under $10 Trending Sharply Higher

8 Stocks Under $10 Trending Sharply Higher

Regardless of the reason behind it, when a stock makes a large-percentage move, it is often just the start of a new major trend -- a trend that can lead to huge profits.

4 Health Care Stocks Under $10 to Watch

4 Health Care Stocks Under $10 to Watch

Regardless of the reason behind it, when a stock makes a large-percentage move, it is often just the start of a new major trend -- a trend that can lead to huge profits.

5 Stocks Poised for Breakouts

5 Stocks Poised for Breakouts

These stocks look ready to break out and trade higher from current levels.

5 Stocks Under $10 Triggering Breakouts

5 Stocks Under $10 Triggering Breakouts

These under-$10 stocks look poised to trade higher from current levels.

Stocks Under $5: Discount Drug Name

Stocks Under $5: Discount Drug Name

Portfolio manager David Peltier analyzes a volatile, low-dollar drug stock.

8 Stocks Under $10 Making Big Moves

8 Stocks Under $10 Making Big Moves

Regardless of the reason behind it, when a stock makes a large-percentage move, it is often just the start of a new major trend -- a trend that can lead to huge profits.

Cadence Pharmaceuticals' Management Presents At The 2012 Wedbush PACGROW Life Sciences Management Access Conference (Transcript)

Cadence Pharmaceuticals' Management Presents At The 2012 Wedbush PACGROW Life Sciences Management Access Conference (Transcript)

Cadence Pharmaceuticals' Management Presents at the 2012 Wedbush PACGROW Life Sciences Management Access Conference (Transcript)